Table 1. Patient, tumor and treatment characteristics.

Characteristic	Total cohort (n=155)	Homogenous cohort (n=100)
Age at diagnosis, years
Mean (95% CI)	65 (64–66)	66 (64–68)
Median (min–max)	65 (39–85)	66 (45–85)
Gender, n (%)
Female	58 (37.4)	40 (40.0)
Male	97 (62.6)	60 (60.0)
Smoking history, n (%)
Positive	140 (90.3)	92 (92.0)
Negative	15 (9.7)	8 (8.0)
Histology, n (%)
Adenocarcinoma	139 (89.7)	100 (100.0)
Squamous cell carcinoma	14 (9.0)	NA
Adenosquamous	1 (0.6)	NA
NOS	1 (0.6)	NA
Grade of differentiation, n (%)
Well differentiated	50 (32.3)	40 (40.0)
Moderately differentiated	56 (36.1)	37 (37.0)
Poorly differentiated	49 (31.6)	23 (23.0)
Tumor size, cm, n (%)
0–1.9	35 (22.6)	29 (29.0)
2–3.9	67 (43.2)	48 (48.0)
4–5.9	31 (20.0)	12 (12.0)
≥6	22 (14.2)	11 (11.0)
pTNM stage (8th edition), n (%)
Stage I	67 (43.2)	54 (54.0)
Stage II	41 (26.5)	21 (21.0)
Stage III	39 (25.2)	25 (25.0)
Stage IV	8 (5.2)	NA
Surgical resection, n (%)
R0	146 (94.2)	100 (100.0)
R1	9 (5.8)	NA
Mutation, positive/tested
p53	19/53	12/36
EGFR	10/107	NA
KRAS	28/63	23/40
Treatment
Neoadjuvant therapy, n (%)	39 (25.2)	NA
Cisplatin- or carboplatin-based doublet chemotherapy	36 (23.2)	NA
Cisplatin- or carboplatin-based doublet with radiotherapy	2 (1.3)	NA
Pembrolizumab with radiotherapy	1 (0.6)	NA
Surgery, n (%)	155 (100.0)	100 (100.0)
Adjuvant therapy, n (%)	46 (29.7)	27 (27.0)
Cisplatin- or carboplatin-based chemotherapy	29 (18.7)	21 (21.0)
Cisplatin- or carboplatin-based chemotherapy with radiotherapy	10 (6.5)	6 (6.0)
Radiotherapy only	7 (4.5)	NA

CI, confidence interval; NA, not applicable; NOS, not otherwise specified; pTNM, pathological tumor-node-metastasis; EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma virus.